In Conversation: John Mumm, Chief Executive Officer, Deka BioSciences

Published on :

John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.

Trevena’s AT1 receptor-selective agonist TRV027 Aimed at COVID-19 in Two Studies

Trevena AT1 TRV027
Published on :

Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.

ATCC Announces Award of HIV Reagent Program

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines and microorganisms.
Published on :

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Published on :

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic Frederick, Maryland, September 26, 2019:  BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and [….]